Allena

Allena Pharmaceuticals is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral enzyme therapeutics for patients with rare and severe metabolic disorders affecting the kidney, including hyperoxaluria and hyperuricosuria. Headquartered in the United States, the company's approach focuses on oral biologics that act locally in the GI tract to reduce pathological metabolite loads, offering a differentiated mechanism from systemic therapies.